Previous reports also suggested that a higher burden of gene copy number loss was associated with the anti-CTLA-4 and anti-PD-1 therapy response and the TP53 gene mutation was negatively associated with survival in the melanoma treated with anti-CTLA4 therapies (Van Allen et al., 2015; Weber et al., 2015; Li et al., 2017; Roh et al., 2017; Seibert et al., 2018; Xiao et al., 2018; Tan et al., 2019; Varga et al., 2019), However, a single gene prediction model was not effective enough to distinguish the responders or non-responders in ICI treatments. This evidence concerns the gene CTLA4 and melanoma.